As its lead compound, telotristat etiprate (LX1032), marches toward the goal line, Lexicon Pharmaceuticals Inc. pocketed $23 million up front as part of a potential $145 million licensing deal with Paris-based Ipsen SA to commercialize the drug outside North America and Japan.